Xeomin® (incobotulinumtoxinA) is the latest contender in a growing list of botulinum toxin type A injectables. The Food and Drug Administration (FDA) approved Xeomin® in July 2011 for the treatment of severe frown lines or “11’s” between the eyes. This Botox® alternative was already approved for use in adults with cervical dystonia and blepharospasm. Cervical dystonia is characterized by abnormal neck pain and movements, and blepharospasm is marked by abnormal, involuntary blinking or spasm of the eyelids. Xeomin® is manufactured by Merz Pharmaceuticals.
With the new cosmetic approval, Xeomin® now joins the ranks of Botox® and Dysport®. Other Botox® alternatives, including a topical form of Botox®, are currently being studied as well. Worldwide, more than 84,000 people have been treated with Xeomin® injections. The U.S. is actually the 20th country to approve this new drug. It will be available in 50-unit and 100-unit vials.
By Arianna Bankovich, RN Introduction: Botox, derived from the bacterium Clostridium botulinum, has long been renowned for its cosmetic applications in reducing wrinkles and fine
By Crystal Wilson, CNP In the dynamic landscape of healthcare, career trajectories often take unexpected turns. One noticeable trend in recent years is the increasing
By Katie Barrer, RDH Who better suited to treat their patients for bruxism than dental hygienists? Two states allow RDHs to administer Botox for